Gemphire Therapeutics Inc (NASDAQ:GEMP) has been given a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company.
Brokers have set a one year consensus target price of $19.00 for the company and are anticipating that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also assigned Gemphire Therapeutics an industry rank of 111 out of 265 based on the ratings given to related companies.
Several research analysts have weighed in on GEMP shares. Jefferies Group started coverage on Gemphire Therapeutics in a research report on Tuesday, August 30th. They set a “buy” rating and a $15.00 price target on the stock. Canaccord Genuity assumed coverage on Gemphire Therapeutics in a report on Tuesday, August 30th. They set a “buy” rating and a $17.00 target price on the stock. Laidlaw assumed coverage on Gemphire Therapeutics in a report on Tuesday, September 6th. They set a “buy” rating and a $20.00 target price on the stock. RBC Capital Markets reissued an “outperform” rating and set a $25.00 target price on shares of Gemphire Therapeutics in a report on Friday, September 16th. Finally, Royal Bank Of Canada assumed coverage on Gemphire Therapeutics in a report on Tuesday, August 30th. They set an “outperform” rating and a $25.00 target price on the stock.
Gemphire Therapeutics (NASDAQ:GEMP) traded up 1.8909% during mid-day trading on Friday, reaching $11.2997. 6,839 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $11.34 and a 200-day moving average price of $10.89. Gemphire Therapeutics has a 52 week low of $8.80 and a 52 week high of $13.98. The stock’s market cap is $104.75 million.
In other news, Director Steven R. Ph.D. Gullans purchased 500,000 shares of Gemphire Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David Lowenschuss purchased 11,120 shares of Gemphire Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The stock was purchased at an average price of $10.00 per share, with a total value of $111,200.00. Following the completion of the purchase, the insider now directly owns 806,247 shares in the company, valued at $8,062,470. The disclosure for this purchase can be found here.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of dyslipidemia. It is developing its product candidate Gemcabene (CI-1027), once-daily, oral therapy, for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.